Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Ho

Showing results (391-400 of 407) with videos related to

Pageof 41
Sort By:
Cancer Research|July 10, 2007
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasomeSusan D Demo, Christopher J Kirk, Monette A Aujay, et al.
Fertility and Sterility|June 2, 2026
NOVEL POLYCYSTIC OVARY SYNDROME CLUSTERS IDENTIFIED BY ENDOCRINE-METABOLIC CLUSTERING: IMPACT ON REPRODUCTIVE OUTCOMES AFTER FERTILITY TREATMENTVu N A Ho, Toan D Pham, Nam T Nguyen, et al.
Journal of Diabetes Science and Technology|November 29, 2024
Consensus Report on the Use of Continuous Glucose Monitoring in Chronic Kidney Disease and DiabetesConnie M Rhee, Roma Y Gianchandani, David Kerr, et al.
Journal of Diabetes Science and Technology|August 15, 2025
CGM Data Analysis 2.0: Functional Data Pattern Recognition and Artificial Intelligence ApplicationsDavid C Klonoff, Richard M Bergenstal, Eda Cengiz, et al.
Nature Medicine|March 31, 2026
Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trialPrincess U Ogbogu, Florence Roufosse, Praveen Akuthota, et al.
Journal of Medicinal Chemistry|April 8, 2009
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)Han-Jie Zhou, Monette A Aujay, Mark K Bennett, et al.
Journal of Diabetes Science and Technology|November 9, 2024
Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery SystemViral N Shah, Anne L Peters, Guillermo E Umpierrez, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Aberrant splicing in Huntington's disease via disrupted TDP-43 activity accompanied by altered m6A RNA modificationThai B Nguyen, Ricardo Miramontes, Carlos Chillon-Marinas, et al.
Science Translational Medicine|October 7, 2016
Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemiaStephen S Y Lam, Eric S K Ho, Bai-Liang He, et al.
Mabs|March 12, 2011
A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activityJianying Dong, Arlene Sereno, Dikran Aivazian, et al.
Pageof 41

Showing results (391-400 of 407) with videos related to

Sort By:
Pageof 41
Cancer Research|July 10, 2007
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasomeSusan D Demo, Christopher J Kirk, Monette A Aujay, et al.
Fertility and Sterility|June 2, 2026
NOVEL POLYCYSTIC OVARY SYNDROME CLUSTERS IDENTIFIED BY ENDOCRINE-METABOLIC CLUSTERING: IMPACT ON REPRODUCTIVE OUTCOMES AFTER FERTILITY TREATMENTVu N A Ho, Toan D Pham, Nam T Nguyen, et al.
Journal of Diabetes Science and Technology|November 29, 2024
Consensus Report on the Use of Continuous Glucose Monitoring in Chronic Kidney Disease and DiabetesConnie M Rhee, Roma Y Gianchandani, David Kerr, et al.
Journal of Diabetes Science and Technology|August 15, 2025
CGM Data Analysis 2.0: Functional Data Pattern Recognition and Artificial Intelligence ApplicationsDavid C Klonoff, Richard M Bergenstal, Eda Cengiz, et al.
Nature Medicine|March 31, 2026
Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trialPrincess U Ogbogu, Florence Roufosse, Praveen Akuthota, et al.
Journal of Medicinal Chemistry|April 8, 2009
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)Han-Jie Zhou, Monette A Aujay, Mark K Bennett, et al.
Journal of Diabetes Science and Technology|November 9, 2024
Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery SystemViral N Shah, Anne L Peters, Guillermo E Umpierrez, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Aberrant splicing in Huntington's disease via disrupted TDP-43 activity accompanied by altered m6A RNA modificationThai B Nguyen, Ricardo Miramontes, Carlos Chillon-Marinas, et al.
Science Translational Medicine|October 7, 2016
Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemiaStephen S Y Lam, Eric S K Ho, Bai-Liang He, et al.
Mabs|March 12, 2011
A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activityJianying Dong, Arlene Sereno, Dikran Aivazian, et al.
Pageof 41